Carl McLain, a grandfather and Parkinson’s disease patient, reports enjoying a much-improved quality of life since undergoing deep brain stimulation (DBS), a surgical treatment generally advised for those failing to respond to other disease therapies. McLain 77, said he began experiencing mysterious leg pain, anxiety, depression, and…
BrainTale raised €4.5 million (about $5 million) to speed further development of software that can decode changes in the brain’s white matter into information that can predict, diagnose, and monitor the progression of diseases such as Parkinson’s. With this round of financing, led by investors Capital Grand…
Coya Therapeutics has secured an exclusive license to patent rights and know-how related to the company’s experimental anti-inflammatory therapy COYA 301, alone or in combination with other molecules, for Parkinson’s disease. The license was part of an agreement with UNeMed, the technology transfer office of the University…
UB-312, an experimental vaccine by Vaxxinity, appeared safe and well tolerated and was able to produce an immune response against toxic alpha-synuclein protein aggregates in people with early Parkinson’s disease, according to data from a clinical trial. According to the company, UB-312 met the primary objectives of the…
Following a positive safety review, Annovis Bio‘s Phase 3 clinical trial testing oral buntanetap for the treatment of early-stage Parkinson’s disease can move forward as originally designed, the company announced. That positive review came from the Data and Safety Monitoring Board (DSMB), an independent group of experts, which…
A history of using inhaled beta-2 adrenoceptor (B2AR) agonists to treat asthma or chronic obstructive pulmonary disorder (COPD) was not associated with a decreased risk of developing Parkinson’s disease, according to a recent Finnish study. The findings contrast earlier epidemiological studies that found these medications, commonly used to treat…
Following promising new data from healthy volunteers in early clinical trials, NodThera now is testing its oral treatment candidate NT-0796 in a Phase 1b/2a biomarker study involving people with Parkinson’s disease. The biotech company announced the positive results from its first-in-human Phase 1 study (ACTRN12621001082897), which found…
People with Parkinson’s who smoke cigarettes or use aspirin tend to report more problems with certain disease symptoms, according to a new study. The study, however, did not find notable associations between drinking coffee and Parkinson’s symptom severity. “This study comprehensively assesses the effect of smoking, coffee drinking, and aspirin…
A framework set up by the Parkinson’s Foundation can help therapists and other professionals design more personalized exercise programs for people with Parkinson’s disease. The competency framework, as it is called, outlines programs, courses, and approaches that help to educate and train movement specialists, given the…
Axial Therapeutics will use a new research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance its experimental therapy for Parkinson’s disease, AX-5006, from ongoing preclinical studies into a first clinical trial in humans. The company is conducting a series of preclinical studies…
Get regular updates to your inbox.
